More North American biotechs, but European and Asian firms hold better assets
This article was originally published in Scrip
North American biotechnology companies are more numerous, but European companies have more projects in development and Asian firms are significantly more clinically oriented. This is the top-line conclusion from Scrip’s analysis of the pipelines of some 1,765 companies which are yet to earn revenues from sales of drugs which shows that the product portfolios of Asian and European companies are significantly broader on average than those of North American companies.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.